With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Drugs - Market Revenue to Cross USD 11 Billion by 2027 - Arizton

2022-11-22
PRNewswire
临床2期临床3期
CHICAGO, Nov. 22, 2022 /PRNewswire/ -- According to Arizton's latest research report, the atopic dermatitis treatment market is expected to reach USD 11.34 billion by 2027. The most common type of eczema is atopic dermatitis. Increasing demand for biologics, the growing burden of allergic reactions, and the anticipated launch of emerging drugs are the major drivers in the market.
Continue Reading
Atopic Dermatitis Treatment Market
Atopic Dermatitis0+ molecules in various stages of development, new vendors are expected to enter the market with novel mechanisms of action with better safety and efficacy profiles than the existing patented commercial drugs for treating atopic dermatitis. Promising late-stage medications with a range of mechanisms of action, including OX-40 antagonists, S1P receptor modulators, tyrosine kinase inhibitors, interleukin inhibitors, and PDE-4 inhibitors, are anticipated to hit the market soon.
Atopic dermatitis is children's most common skin disease, with prevalence steadily increasing from 8% to 12% in the last two decades. It is distinguished by a defect in the skin barrier that allows allergens and other irritants to enter thatopic dermatitis in an immune response and inflammation. This reaction causes a red, itchy rash thaOX-40 antagonistsppS1P receptor modulators atyrosine kinasecan cover large areas of the body. The inPDE-4ation causes severe pruritus (itching), resulting in damage from scratching or rubbing, perpetuating an 'itch-scratch' cycle. Pediatric patients with atopic dermatitis can suffer from sleep disturbances, behavioral problems, irritability, crying, and interference with normal childhood activities and social functioning. Adults with atopic dermatitis also frequently suffer from sleep disturbances, emotional impacts, and impaired social functioning.
Atopic Dermatitisthe other trends impacting the future of the market and the positive and negative consequences on the businesses; click to get a free sample report now.
Key Insights
The United States accounted for more than 60% of the global atopic dermatitis therapeutics market. Due to the rise in the prevalence of atopic dermatitis, the presence of key players, the increase in healthcare affordability in the US, knowledge, and awareness amongst the people, and technological advancement are the major drivers in this region.
Topical corticosteroids accounted for a significant share ofatopic dermatitis of the global atopic dermatitis therapeutics due to their atopic dermatitison in the front-line setting. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period.
Women accounted for a share of 51.03% in global atopic dermatitis. This is due to women beinatopic dermatitisicant risk of atopic dermatitis in recent years.
Among the severity, mild form accounted for a siatopic dermatitisf 45.28% in the global atopic dermatitis therapeutics markatopic dermatitisrate form is expected to be the fastest-growing segment during the forecast period.
Report Coversatopic dermatitis
Detailed overview of the atopic dermatitis treatment market, including disease definition, classification, diagnosis, and treatment pattern
Overview of the global tratopic dermatitisrmatitis in the eight major markets (8MM)
Historical, current, and projecteatopic dermatitis atopic dermatitis in the eight major markets (8MM) for 2018 – 2027
In-depth market segment analysis, including productatopic dermatitis competitor analysis
Atopic dermatitis treatment market share of the market players, company profiles, product specifications, and competitive landscape
Atopic dermatitisa on emerging trends, market drivers, growth opportunities, and restraints
Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Atopic Dermatitis across the complete product development cycle, including all clinical and non-clinical stages
Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for Atopic Dermatitis across all clinical stages
Coverage of dormant and discontinued pipeline projects, along with the reasons across the atopic dermatitis treatment marketatopic dermatitis
Coverage of significant milestones (product approvals/launches timelines, clinical trial ratopic dermatitiss, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the atopic dermatitis space
Atopic Dermatitis: Clinical Trials Scenarioatopic dermatitis
Atopic Dermatitisl portfolio contains 153+ trials in various development phases. Most industry-sponsored drugs in active clinical development for atopic dermatitis are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that most trials for atopic dermatitis have been in the mid-phase of development, with 47% of trials in Phase I/II & II and only 29% in Phase II/III-III.
Drug Class
Topical Steroids
Topical Calcineurin Inhibitors
Gender Type
Men
Women
Age Group
18 years and Below
19 years and Above
Severity Type
Moderate
Mild
Severe
Geography
North America
The U.S.
APAC
China
Japan
Europe
France
Germany
UK
Italy
Spain
Key Leading Vendors
LEO Pharma
Pfizer/Regeneron
AbbVielly and Company
Vanda Pharmaceuticals
CARA TherapeuticsAstraZeneca)
Asana
Asana Biosciences
BiomXme Therapeutics, Inc.
Amytrxherapeutics
BenevolentAI Ltd
Novan, Inc.
Novan, Inc.me of the Top-Selling Related Reports
Psoriatic Arthritis Treatment Market Forecast - The global psoriatic arthritis treatment market is expected to reach USD 12.46 billion by 2027, from USD 7.81 billion in 2021. The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage.  The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm soon.
Psoriatic Arthritisrapeutics Market Forecast -  The Crohn'spsoriatic arthritiscs market is expected to grow at a CAGR of 10.35% during 2022-2027. The Crohn's Disease portfolio conpsoriatic arthritis0+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for Crohn's Disease are in the Phase II stage. Anti-ipsoriatic arthritisgrin antibodies are dominating the Crohn's Disease drug pipepsoriatic arthritisBimekizumabTildrakizumabSHR-0302NeihulizumabPsA
Crohn's Diseasetis Market Forecast -  The ulcerativeCrohn's disease was valued at USD 7.24 billion in 2021 and is expected to reach USD 12 Billion by Crohn's Diseasecal trial portfolio contains 155+ trials in various development phases. Most industry-sponsored drugs in active clinical development for inflammatory bCrohn's Diseasee in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trialCrohn's DiseaseI-IV indicates that most trials for ulcerative colitis have been in the early and mid-phases of development, with 84% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of ulcerative colitis clinical trials globally.
Ulcerative ColitisDisease Treatment Marketulcerative colitisVersus Host Disease treatment market was valued at USD 643 million in 2021 and is expected to reach USD 990 million by 2027. The United States dominated the graft versus host disease treatment market. However, China is expected to grow fasterinflammatory bowel diseasee in incidence and prevalence of GVHD patients, the presence of key players, and the increase in access to health care due to well-establishedulcerative colitistructure and extensive reach of novel therapeutics are mainly driving the United States market.ulcerative colitis
1. ATOPIC DERMATITIS OVERVIEW
1.1ATOPIC DERMATITISis Disease – An Overview
2. ATAtopic Dermatitis DiseaseOGY & OVERVIEW
2.1ATOPIC DERMATITIS Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.3. 8MM: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.4. 8MM: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.5. 8MM: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.6. 8MM: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.7. US: Historic & Projected Volume of Incidence & PreAtopic Dermatitis DermatitiAge Group
2.8. US: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.9. US: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.10. US: Historic & Projected Volume of Incidence ofAtopic Dermatitiss cases by Age Group
2.11. US: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.12. US: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.13. China: Historic & Projected Volume of Incidence &Atopic Dermatitisopic DermaAge Group
2.14. China: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.15. China: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.16. China: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.17. China: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.18. China: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.19. Japan: Historic & Projected Volume of Incidence & PrAtopic Dermatitisc DermatitAge Group
2.20. Japan: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.21. Japan: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.22. Japan: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.23. Japan: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.24. Japan: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.25. Germany: Historic & Projected Volume of Incidence & Atopic Dermatitispic DermatAge Group
2.26. Germany: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.27. Germany: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.28. Germany: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.29. Germany: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.30. Germany: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.31. UK: Historic & Projected Volume of Incidence & PrevaleAtopic DermatitismatitisAge Group
2.32. UK: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.33. UK: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.34. UK: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.35. UK: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.36. UK: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.37. France: Historic & Projected Volume of Incidence Atopic Dermatitistopic DermAge Group
2.38. France: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.39. France: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.40. France: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.41. France: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.42. France: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.43. Italy: Historic & Projected Volume of Incidence & PreAtopic Dermatitis DermatitiAge Group
2.44. Italy: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.45. Italy: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.46. Italy: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.47. Italy: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.48. Italy: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.49. Spain: Historic & Projected Volume of Incidence & PrAtopic Dermatitisc DermatitAge Group
2.50. Spain: Comparative Analysis of Incidence & Prevalence of Atopic Atopic Dermatitis
2.51. Spain: Historic & Projected Volume of Incidence of AtopicAtopic Dermatitis by Severity Type
2.52. Spain: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.53. Spain: Historic & Projected Volume of Prevalence ofAtopic Dermatitiss cases byAge Group Type
2.54. Spain: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
3. ATOPIC DERMATITIS MARKET SIZE & OVERVIEWAtopic DermatitisAge Group
3.1ATOPIC DERMATITIS Projected Revenue of Atopic Dermatitis
3.2. 8MM: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.3. 8MM: Major Approved Drugs in Atopic DAtopic Dermatitis
3.4. 8MM: Historic & Projected RevAtopic Dermatitis by Gender Type, Severity, Age Group & Drug Class
3.5. US: Historic & Projected Revenue of Atopic Dermatitis
3.6. US: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.7. US: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.8. China: Historic & Projected Revenue of Atopic Dermatitis
3.9. China: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.10. China: Historic & Projected Revenue SeAtopic Dermatitisder Type, Severity, Age Group & Drug Class
3.11. Germany: Historic & Projected Revenue of Atopic Dermatitis
3.12. Germany: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.13. Germany: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.14. Japan: Historic & Projected Revenue of Atopic Dermatitis
3.15. Japan: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.16. Japan: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.17. France: Historic & Projected Revenue of Atopic Dermatitis
3.18. France: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.19. France: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.20. Italy: Historic & Projected Revenue of Atopic Dermatitis
3.21. Italy: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.22. Italy: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.23. UK: Historic & Projected Revenue of Atopic Dermatitis
3.24. UK: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.25. UK: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
3.26. Spain: Historic & Projected Revenue of Atopic Dermatitis
3.27. Spain: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.28. Spain: Historic & Projected Revenue SegAtopic Dermatitiser Type, Severity, Age Group & Drug Class
4. ATOPIC DERMATITIS MARKETED DRUGS OVERVIEW
4.1ATOPIC DERMATITISis Marketed Drugs – An Overview
4.2. Atopic Dermatitis Marketed Drugs – Summary
5. ATAtopic DermatitisIPELINE DRUGS OVERVIEW
5.1ATOPIC DERMATITISis Pipeline Drugs – An Overview
5.2. Atopic Dermatitis Pipeline Drugs – Snapshot
5.3. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Disease type
5.4. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Development Phase
5.5. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Route of Administration
5.6. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Mechanism of Action
5.7. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Molecule type
5.8. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Geography type
6. ATAtopic DermatitisLINICAL TRIALS OVERVIEW
6.1ATOPIC DERMATITISis Clinical Trials Overview Snapshot
6.2. Atopic Dermatitis Clinical Trials Overview – By Recruitment Status
6.3. Atopic Dermatitis Clinical Trials Overview – By Product type
6.4. Atopic Dermatitis Clinical Trials Overview – By Route of Administration
6.5. Atopic Dermatitis Clinical Trials Overview – By Molecule type
6.6. Atopic Dermatitis Clinical Trials Overview – By Geography type
7. ATAtopic DermatitisARKET DYNAMICS
7.1ATOPIC DERMATITISis Therapeutics Market Drivers
7.2. Atopic Dermatitis Therapeutics Market Constraints
7.3. Atopic Dermatitis Therapeutics Market Trends
8. ATAtopic DermatitisOMPETITIVE LANDSCAPE
8.1ATOPIC DERMATITISis Competitive Landscape – Marketed Drugs
8.3. Other Key Company Profiles
8.4. Competitive Scenario of Atopic Dermatitis therapeutics market
8.5. Key Company OverviewsAtopic Dermatitis
8.6. Atopic Dermatitis Competitive Landscape – Pipeline Drugs
8.7. Atopic Dermatitisany Profiles
8.8. Other Key Emerging Company Profiles
8.9. Key Company Overviews
9. ATOPIC DERMATITIS MISCELLANEOUS
9.1ATOPIC DERMATITISrug Approvals Timeline
9.2. Key Regulatory Designations
9.3. Key Milestones
9.4. Deals & Collaborations
9.5. Inactive/Discontinued/Dormant Products
10. APPENDIX
10.1. About Arizton
10.2. Research Methodology
10.3. List of Abbreviations
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, IT and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Click Here to Contact Us
Call: +1-312-235-2040
+1 302 469 0707
Mail: [email protected]
Photo:  https://mma.prnewswire.com/media/1953636/altopic_V1.jpg
Logo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg
SOURCE Arizton Advisory & Intelligence
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。